[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hodgins et al., 2019 - Google Patents

Killers 2.0: NK cell therapies at the forefront of cancer control

Hodgins et al., 2019

View HTML
Document ID
15720839389931237484
Author
Hodgins J
Khan S
Park M
Auer R
Ardolino M
et al.
Publication year
Publication venue
The Journal of clinical investigation

External Links

Snippet

Natural killer (NK) cells are innate cytotoxic lymphocytes involved in the surveillance and elimination of cancer. As we have learned more and more about the mechanisms NK cells employ to recognize and eliminate tumor cells, and how, in turn, cancer evades NK cell …
Continue reading at www.jci.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Similar Documents

Publication Publication Date Title
Hodgins et al. Killers 2.0: NK cell therapies at the forefront of cancer control
Sivori et al. NK cells and ILCs in tumor immunotherapy
Ben-Shmuel et al. Unleashing natural killer cells in the tumor microenvironment–the next generation of immunotherapy?
Li et al. Tumor immunotherapy: new aspects of natural killer cells
Guillerey et al. Targeting natural killer cells in cancer immunotherapy
Zhang et al. Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy
Prieto et al. Immunological landscape and immunotherapy of hepatocellular carcinoma
Leone et al. Actors on the scene: immune cells in the myeloma niche
ES2967467T3 (en) Combination of a cell therapy and an immunomodulatory compound
Chester et al. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy
Dai et al. Chimeric antigen receptors modified T-cells for cancer therapy
Elahi et al. Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects
Ljunggren et al. Prospects for the use of NK cells in immunotherapy of human cancer
Riches et al. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia
EP3436480A1 (en) Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
JP2024073656A (en) Nkt cell subset for in vivo persistence and therapeutic activity and propagation of same
Colomar-Carando et al. Exploiting natural killer cell engagers to control pediatric B-cell precursor acute lymphoblastic leukemia
Danhof et al. CARs and other T cell therapies for MM: the clinical experience
JP2022512161A (en) Compositions and Methods for Immunotherapy
Cristiani et al. New avenues for melanoma immunotherapy: Natural Killer cells?
JP2024525475A (en) Engineered immune cells to promote tanotransmission and uses thereof
Yang et al. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
Chen et al. Natural killer cells: the next wave in cancer immunotherapy
Wang et al. CD8+ T cells in immunotherapy, radiotherapy, and chemotherapy
Kroesen et al. Immunocombination therapy for high-risk neuroblastoma